Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this multicentered phase II trial (NCT04303741), 46 patients with pretreated advanced TNBC were enrolled to receive camreliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jieqiong, Wang, Ying, Tian, Zhenluan, Lin, Ying, Li, Hengyu, Zhu, Zhaowen, Liu, Qiang, Su, Shicheng, Zeng, Yinduo, Jia, Weijuan, Yang, Yaping, Xu, Shengqiang, Yao, Herui, Jiang, Wen, Song, Erwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156739/
https://www.ncbi.nlm.nih.gov/pubmed/35641481
http://dx.doi.org/10.1038/s41467-022-30569-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156739/
https://www.ncbi.nlm.nih.gov/pubmed/35641481
http://dx.doi.org/10.1038/s41467-022-30569-0

Ejemplares similares